In Vivo Evaluation of Taste-Masked Fast-Disintegrating Sublingual Tablets of Epinephrine Microcrystals
In community settings, IM injection of 0.3 mg epinephrine (Epi) using an auto-injector is the drug of choice for treatment of anaphylaxis. Previously, a taste-masking (TM) formulation of fast-disintegrating sublingual tablets (FDSTs) was developed in our lab. Also, Epi was micronized (Epi-MC) successfully and reduced the previously achieved bioequivalent sublingual Epi dose to 0.3 mg IM injection by half using non-taste-masked fast-disintegrating sublingual tablets (TM-FDSTs). Our objective for this study was to evaluate the sublingual absorption of Epi-MC using TM-FDST. These sublingual Epi tablets have potential for out-of-hospital treatment of anaphylaxis and are suitable for human studies. TM-FDSTs containing Epi-MC were manufactured by direct compression. The rate and extent of Epi absorption from our developed 20 mg Epi-MC-TM-FDSTs (n = 5) were evaluated in rabbits and compared to the previous result from 20 mg Epi-MC in non-TM-FDSTs and EpiPen® auto-injector. Blood samples were collected over 1 h, and Epi concentrations were measured using HPLC with electrochemical detection. Mean ± SEM AUC0–1 h and Cmax from 20 mg Epi-MC-TM-FDSTs (733 ± 78 ng/ml/min and 30 ± 8 ng/ml) and 20 mg Epi-MC-non-TM-FDSTs (942 ± 109 ng/ml/min and 38 ± 4 ng/ml) were not significantly different (p > 0.05) from each other or from EpiPen® (592 ± 50 ng/ml/min and 28 ± 3 ng/ml) but were significantly higher (p < 0.05) than endogenous Epi after placebo FDSTs (220 ± 32 ng/ml/min and 8 ± 1 ng/ml). Mean ± SD Tmax was not significantly different (p > 0.05) among all formulations. Epi-MC-TM-FDSTs formulation improved Epi absorption twofold and reduced the required bioequivalent dose by 50%, similar to results obtained using non-TM-FDSTs. The incorporation of TM excipients did not interfere with the absorption of Epi-MC.
KEY WORDSabsorption adrenaline anaphylaxis epinephrine microcrystals sublingual tablets
Compliance with Ethical Standards
The protocol for the in vivo study, which was performed in a validated rabbit model, was reviewed and approved by the Protocol Management and Review Committee in the University of Manitoba. The guidelines of the Canadian Council on Animal Care were followed (36).
Conflict of Interest
The authors declare that they have no conflict of interest.
- 8.Palmer E. FDA slams Pfizer unit responsible for EpiPens that failed during fatal emergencies. In: FiercePharma, Questex LLC. 2017. https://www.fiercepharma.com/pharma/fda-slams-pfizer-unit-made-epipens-failed-during-fatal-emergencies. Accessed 6 Oct 2017.
- 9.Scutti S. ‘Short-term’ EpiPen shortage, anticipates FDA. In: Cable News Network. Turner Broadcasting System, Inc. 2018. https://edition.cnn.com/2018/05/09/health/epipen-fda-drug-shortages-list-bn/index.html. Accessed 6 Jun 2018.
- 10.Kim L, Nevis IF, Tsai G, Dominic A, Potts R, Chiu J, et al. Children under 15 kg with food allergy may be at risk of having epinephrine auto-injectors administered into bone. Allergy Asthma Clin Immunol. 2014;10(1):40. https://doi.org/10.1186/1710-1492-10-40.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Dreborg S, Wen X, Kim L, Tsai G, Nevis I, Potts R, et al. Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy? Allergy Asthma Clin Immunol. 2016;12:11. https://doi.org/10.1186/s13223-016-0110-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Rawas-Qalaji MM, Simons FE, Simons KJ. Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability? Biopharm Drug Dispos. 2006;27(9):427–35. https://doi.org/10.1002/bdd.519.CrossRefPubMedGoogle Scholar
- 23.Rachid O, Simons FE, Rawas-Qalaji MM, Simons KJ. An electronic tongue: evaluation of the masking efficacy of sweetening and/or flavoring agents on the bitter taste of epinephrine. AAPS PharmSciTech. 2010;11(2):550–7. https://doi.org/10.1208/s12249-010-9402-3.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Rawas-Qalaji MM, Werdy S, Rachid O, Simons FE, Simons KJ. Sublingual diffusion of epinephrine microcrystals from rapidly disintegrating tablets for the potential first-aid treatment of anaphylaxis: in vitro and ex vivo study. AAPS PharmSciTech. 2015;16(5):1203–12.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Physical Tests. Uniformity of dosage units. In: USP/NF, 26/21 ed. Rockville: United States Pharmacopeial Convention Inc.; 2003.Google Scholar
- 35.Official Monograph. Epinephrine injection. In: USP/NF, 32/27 ed., Rockville: United States Pharmacopeial Convention Inc.; 2009. p. 2261.Google Scholar
- 36.Olfert ED, Cross BM, McWilliam AA. Guide to the care and use of experimental animals. 2nd ed. Canadian Council on Animal Care: Ottawa; 1993.Google Scholar
- 44.FDA In Brief: FDA takes additional action to mitigate shortages of EpiPen by extending expiration date for specific lots of medication. In U.S. Food and Drug Administration; Maryland (USA). 2018. https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm617724.htm?utm_campaign=08212018_FiB_FDA%20extends%20expiry%20date%20for%20specific%20EpiPen%20lots%20to%20mitigate%20shortages&utm_medium=email&utm_source=Eloqua. Accessed 23 Aug 2018.
- 48.Hanson GR. Diuretic drugs. In: Gennaro AR, editor. Remington: the science and practice of pharmacy. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 1344–53.Google Scholar
- 50.Committee for Medicinal Products for Human Use (CHMP). Reflection paper: formulations of choice for the paediatric population. EMEA/CHMP/PEG/194810/2005. In European Medicines Agency; London (UK). 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf. Accessed 11 Mar 2017.